A Multi-center, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 Implantation for the Prevention of Corneal Allograft Rejection Episodes or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Trial Profile

A Multi-center, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 Implantation for the Prevention of Corneal Allograft Rejection Episodes or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2012

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Keratoplasty rejection
  • Focus Therapeutic Use
  • Acronyms LUCIDA
  • Most Recent Events

    • 13 Oct 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2007-000294-33 ).
    • 13 Oct 2012 Planned number of patients changed from 240 to 400.
    • 08 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top